Key Points
- Director Kevin Bitterman sold roughly 368,462 shares of Disc Medicine between Oct. 7 and Dec. 17, including 754 shares on Dec. 17 at $91.47, generating about $31.3 million in proceeds.
- Following the Dec. 17 sale he still owns 14,013 shares (about $1.28M); Disc Medicine is trading up 3.4%, has a market cap of $3.41B, and carries a consensus analyst target of $119 ("Moderate Buy").
Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) Director Kevin Bitterman sold 754 shares of the company's stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $91.47, for a total value of $68,968.38. Following the sale, the director owned 14,013 shares of the company's stock, valued at approximately $1,281,769.11. This represents a 5.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Kevin Bitterman also recently made the following trade(s):
- On Friday, December 12th, Kevin Bitterman sold 45,507 shares of Disc Medicine stock. The shares were sold at an average price of $92.39, for a total value of $4,204,391.73.
- On Tuesday, December 16th, Kevin Bitterman sold 68,923 shares of Disc Medicine stock. The stock was sold at an average price of $91.24, for a total value of $6,288,534.52.
- On Monday, December 15th, Kevin Bitterman sold 62,693 shares of Disc Medicine stock. The stock was sold at an average price of $91.28, for a total transaction of $5,722,617.04.
- On Monday, December 15th, Kevin Bitterman sold 7,000 shares of Disc Medicine stock. The shares were sold at an average price of $91.87, for a total transaction of $643,090.00.
- On Friday, October 17th, Kevin Bitterman sold 70,000 shares of Disc Medicine stock. The stock was sold at an average price of $88.91, for a total transaction of $6,223,700.00.
- On Thursday, October 16th, Kevin Bitterman sold 1,425 shares of Disc Medicine stock. The shares were sold at an average price of $77.11, for a total transaction of $109,881.75.
- On Wednesday, October 15th, Kevin Bitterman sold 22,160 shares of Disc Medicine stock. The shares were sold at an average price of $77.23, for a total transaction of $1,711,416.80.
- On Wednesday, October 8th, Kevin Bitterman sold 71,961 shares of Disc Medicine stock. The stock was sold at an average price of $70.58, for a total transaction of $5,079,007.38.
- On Tuesday, October 7th, Kevin Bitterman sold 18,039 shares of Disc Medicine stock. The shares were sold at an average price of $68.38, for a total value of $1,233,506.82.
Disc Medicine Trading Up 3.4%
NASDAQ IRON opened at $90.44 on Friday. The company has a market cap of $3.41 billion, a price-to-earnings ratio of -16.90 and a beta of 0.87. Disc Medicine, Inc. has a twelve month low of $30.82 and a twelve month high of $99.50. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05. The business's fifty day moving average is $87.72 and its 200 day moving average is $68.51.
Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.48) by ($0.29). As a group, sell-side analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in Disc Medicine by 22.2% during the first quarter. Vanguard Group Inc. now owns 1,305,046 shares of the company's stock worth $64,782,000 after acquiring an additional 236,800 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Disc Medicine by 18.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 194,725 shares of the company's stock valued at $9,666,000 after purchasing an additional 29,653 shares during the period. Swiss National Bank boosted its position in shares of Disc Medicine by 11.5% during the 1st quarter. Swiss National Bank now owns 35,900 shares of the company's stock worth $1,782,000 after purchasing an additional 3,700 shares in the last quarter. Invesco Ltd. boosted its position in shares of Disc Medicine by 27.1% during the 1st quarter. Invesco Ltd. now owns 13,834 shares of the company's stock worth $687,000 after purchasing an additional 2,953 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Disc Medicine in the 1st quarter valued at about $5,595,000. Institutional investors and hedge funds own 83.70% of the company's stock.
Analyst Ratings Changes
A number of research analysts recently issued reports on IRON shares. National Bankshares set a $153.00 price objective on shares of Disc Medicine in a report on Friday, October 17th. Raymond James Financial reaffirmed a "strong-buy" rating and set a $117.00 price target on shares of Disc Medicine in a research note on Monday, December 8th. Wells Fargo & Company boosted their price objective on shares of Disc Medicine from $91.00 to $109.00 and gave the stock an "overweight" rating in a research note on Tuesday. Wedbush raised their target price on Disc Medicine from $90.00 to $110.00 and gave the stock an "outperform" rating in a research report on Friday, October 17th. Finally, Morgan Stanley lifted their target price on Disc Medicine from $90.00 to $115.00 and gave the stock an "overweight" rating in a report on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $119.00.
Read Our Latest Stock Analysis on IRON
About Disc Medicine
(
Get Free Report)
Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
